A multicenter, retrospective medical record review of X‐linked myotubular myopathy: The recensus study

Introduction: X‐linked myotubular myopathy (XLMTM), characterized by severe hypotonia, weakness, respiratory distress, and early mortality, is rare and natural history studies are few. Methods: RECENSUS is a multicenter chart review of male XLMTM patients characterizing disease burden and unmet medical needs. Data were collected between September 2014 and June 2016. Results: Analysis included 112 patients at six clinical sites. Most recent patient age recorded was ≤18 months for 40 patients and >18 months for 72 patients. Mean (SD) age at diagnosis was 3.7 (3.7) months and 54.3 (77.1) months, respectively. Mortality was 44% (64% ≤18 months; 32% >18 months). Premature delivery occurred in 34/110 (31%) births. Nearly all patients (90%) required respiratory support at birth. In the first year of life, patients underwent an average of 3.7 surgeries and spent 35% of the year in the hospital. Discussion: XLMTM is associated with high mortality, disease burden, and healthcare utilization. Muscle Nerve 57: 550–560, 2018

[1]  J. Martin,et al.  Births: Final Data for 2017. , 2018, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[2]  Shuling Guo,et al.  Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice , 2017, Nature Communications.

[3]  R. Grange,et al.  Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  J. Dowling,et al.  PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models. , 2016, The Journal of clinical investigation.

[5]  J. Dowling,et al.  Skeletal Muscle Pathology in X-Linked Myotubular Myopathy: Review With Cross-Species Comparisons , 2016, Journal of neuropathology and experimental neurology.

[6]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[7]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[8]  J. Vissing,et al.  Frequency and Phenotype of Myotubular Myopathy Amongst Danish Patients with Congenital Myopathy Older than 5 Years , 2015, Journal of neuromuscular diseases.

[9]  Joshua J Gagne,et al.  Innovative research methods for studying treatments for rare diseases: methodological review , 2014, BMJ : British Medical Journal.

[10]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[11]  N. Romero,et al.  Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. , 2014, The Journal of clinical investigation.

[12]  R. Grange,et al.  Gene Therapy Prolongs Survival and Restores Function in Murine and Canine Models of Myotubular Myopathy , 2014, Science Translational Medicine.

[13]  D. Herr,et al.  Polyhydramnios: Causes, Diagnosis and Therapy. , 2013, Geburtshilfe und Frauenheilkunde.

[14]  R. Grange,et al.  Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy. , 2013, Human molecular genetics.

[15]  J. Dowling,et al.  Large duplication in MTM1 associated with myotubular myopathy , 2013, Neuromuscular Disorders.

[16]  J. T. Dunnen,et al.  Expanding the MTM1 mutational spectrum: novel variants including the first multi-exonic duplication and development of a locus-specific database , 2012, European Journal of Human Genetics.

[17]  A. Beggs,et al.  Clinical utility gene card for: Centronuclear and myotubular myopathies , 2012, European Journal of Human Genetics.

[18]  L. Kunkel,et al.  MTM1 mutation associated with X-linked myotubular myopathy in Labrador Retrievers , 2010, Proceedings of the National Academy of Sciences.

[19]  A. Buj-Bello,et al.  AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis , 2008, Human molecular genetics.

[20]  A. Beggs,et al.  Myofiber size correlates with MTM1 mutation type and outcome in X-linked myotubular myopathy , 2007, Neuromuscular Disorders.

[21]  R. Gearing,et al.  A methodology for conducting retrospective chart review research in child and adolescent psychiatry. , 2006, Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent.

[22]  Wuh-Liang Hwu,et al.  A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. , 2006, Jornal de Pediatria.

[23]  A. Beggs,et al.  X-Linked Myotubular and Centronuclear Myopathies , 2005, Journal of neuropathology and experimental neurology.

[24]  D. Hess.  Retrospective studies and chart reviews. , 2004, Respiratory care.

[25]  H. Harn,et al.  X-linked centronuclear myopathy. , 2003, American journal of perinatology.

[26]  M. Krawczak,et al.  Genotype–phenotype correlations in X-linked myotubular myopathy , 2002, Neuromuscular Disorders.

[27]  Soma Das,et al.  Characterization of mutations in fifty North American patients with X‐linked myotubular myopathy , 2002, Human mutation.

[28]  J. Mandel,et al.  The myotubularin family: from genetic disease to phosphoinositide metabolism. , 2001, Trends in genetics : TIG.

[29]  G. Superti-Furga,et al.  Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway. , 2000, Human molecular genetics.

[30]  C. Wallgren‐Pettersson,et al.  MTM1 mutations in X‐linked myotubular myopathy , 2000, Human mutation.

[31]  E. Brown,et al.  The Medical Dictionary for Regulatory Activities (MedDRA) , 1999, Drug safety.

[32]  Wei Zhao,et al.  Medical complications in long-term survivors with X-linked myotubular myopathy. , 1999, The Journal of pediatrics.

[33]  J. Mandel,et al.  Characterization of the myotubularin dual specificity phosphatase gene family from yeast to human. , 1998, Human molecular genetics.

[34]  S. Klauck,et al.  A gene mutated in X–linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast , 1996, Nature Genetics.

[35]  L. Kozak,et al.  Hospital use by children in the United States and Canada. , 1984, Vital and health statistics. Series 5, Comparative international vital and health statistics reports.

[36]  J. Osborne,et al.  THIN RIBS ON CHEST X‐RAY; A USEFUL SIGN IN THE DIFFERENTIAL DIAGNOSIS OF THE FLOPPY NEWBORN , 1983, Developmental medicine and child neurology.

[37]  S. Friant,et al.  WANTED - Dead or alive: Myotubularins, a large disease-associated protein family. , 2017, Advances in biological regulation.

[38]  M. Field,et al.  Committee on Accelerating Rare Diseases Research and Orphan Product Development , 2010 .

[39]  M. Field,et al.  Rare Diseases and Orphan Products , 2010 .

[40]  Orphanet Journal of Rare Diseases BioMed Central Review , 2008 .